Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dotinurad. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 known ✓ | Q96S37 | 16/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dotinurad SCHEMBL29935445 | 1.00 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2HSD11B1SLC22A6 | |
| Dotinurad SCHEMBL28372873 | 0.99 | SLC22A12 (0.97) | SLC22A12CYP2C9ABCG2HSD11B1SLC22A6 | |
| Dotinurad SCHEMBL27088403 | 0.99 | SLC22A12 (0.97) | SLC22A12CYP2C9ABCG2HSD11B1SLC22A6 | |
| Dotinurad SCHEMBL29994905 | 0.99 | SLC22A12 (0.97) | SLC22A12CYP2C9ABCG2HSD11B1SLC22A6 | |
| SCHEMBL10322774 | 0.91 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2 | |
| SCHEMBL10323732 | 0.91 | SLC22A12 (0.84) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| SCHEMBL10322851 | 0.88 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| SCHEMBL10322041 | 0.88 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| SCHEMBL10323387 | 0.88 | SLC22A12 (0.78) | SLC22A12CYP2C9ABCG2 | |
| SCHEMBL10322939 | 0.88 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431270-A | Multi-tenor preparation method of German | 南京联智医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3617199-B1 | CRYSTAL FORM AND SALT OF 3-(3,5-DICHLORO-4-HYDROXYBENZOYL)-1,1-DIOXO-2,3-DIHYDRO-1,3-BENZOTHIAZOLE | FUJI YAKUHIN CO LTD (JP) | 2023-07-26 | — | — | EP | claimed |
| CN-110914246-B | Crystalline forms of 3- (3, 5-dichloro-4-hydroxybenzoyl) -1, 1-dioxo-2, 3-dihydro-1, 3-benzothiazole and salts thereof | 株式会社富士药品 | 2023-03-10 | — | — | CN | claimed |
| US-20230050931-A1 | SOLID PHARMACEUTICAL PREPARATION | FUJI YAKUHIN CO., LTD. (JP) | 2023-02-16 | — | — | US | claimed |
| EP-4074313-A1 | SOLID PHARMACEUTICAL PREPARATION | Fuji Yakuhin Co., Ltd. (JP) | 2022-10-19 | — | — | EP | claimed |
| WO-2021117697-A1 | SOLID PHARMACEUTICAL PREPARATION | 株式会社富士薬品 | 2021-06-17 | — | — | WO | claimed |
| EP-3617199-A9 | CRYSTAL FORM AND SALT OF 3-(3,5-DICHLORO-4-HYDROXYBENZOYL)-1,1-DIOXO-2,3-DIHYDRO-1,3-BENZOTHIAZOLE | Fuji Yakuhin Co., Ltd. (JP) | 2021-03-17 | — | — | EP | claimed |
| US-10752601-B2 | Crystal form and salt of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole | FUJI YAKUHIN CO., LTD (JP) | 2020-08-25 | — | — | US | claimed |
| CN-110914246-A | Crystal forms of 3- (3, 5-dichloro-4-hydroxybenzoyl) -1, 1-dioxo-2, 3-dihydro-1, 3-benzothiazole and salts thereof | 株式会社富士药品 | 2020-03-24 | — | — | CN | claimed |
| EP-3617199-A1 | CRYSTAL FORM AND SALT OF 3-(3,5-DICHLORO-4-HYDROXYBENZOYL)-1,1-DIOXO-2,3-DIHYDRO-1,3-BENZOTHIAZOLE | Fuji Yakuhin Co., Ltd. (JP) | 2020-03-04 | — | — | EP | claimed |
| EP-2484669-B1 | PHENOL DERIVATIVES | FUJI YAKUHIN CO LTD (JP) | 2015-07-29 | — | — | EP | claimed |
| CN-122059904-A | Synthetic multi-substituted method for preparing North Rate | 重庆圣华曦药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122059904-A | Synthetic multi-substituted method for preparing North Rate | 重庆圣华曦药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-121800743-A | Recrystallization method of dorranolazine and application thereof | 武汉武药科技有限公司 | 2026-04-07 | — | — | CN | disclosed |
| CN-121226282-A | Compound bulk drug, pharmaceutical composition and application thereof | 武汉武药科技有限公司 | 2025-12-30 | — | — | CN | disclosed |
| WO-2018199277-A1 | CRYSTAL FORM AND SALT OF 3-(3,5-DICHLORO-4-HYDROXYBENZOYL)-1,1-DIOXO-2,3-DIHYDRO-1,3-BENZOTHIAZOLE | 株式会社富士薬品 | 2018-11-01 | — | — | WO | disclosed |
| EP-2484669-B1 | PHENOL DERIVATIVES | FUJI YAKUHIN CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8367843-B2 | Phenol derivative | FUJI YAKUHIN CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-2484669-A1 | NOVEL PHENOL DERIVATIVE | Fuji Yakuhin Co., Ltd. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184587-A1 | NOVEL PHENOL DERIVATIVE | FUJI YAKUHIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050931-A1 | SOLID PHARMACEUTICAL PREPARATION | SLC5A1, SLC5A2, SORD | SLC22A12 1386/4885CYP2C9 377/4885ABCG2 110/4885 |
| US-20120184587-A1 | NOVEL PHENOL DERIVATIVE | XDH, REN, UTS2R | SLC22A12 379/4885CYP2C9 184/4885ABCG2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.